Get the Stockscreener App
1.80
62.16%
0.69
After Hours:
1.68
-0.12
-6.67%
Immuron Limited Adr stock is traded at $1.80, with a volume of 121.69M.
It is up +62.16% in the last 24 hours and up +66.67% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
See More
Previous Close:
$1.11
Open:
$1.81
24h Volume:
121.69M
Relative Volume:
64.80
Market Cap:
$14.53M
Revenue:
$4.83M
Net Income/Loss:
$-2.99M
P/E Ratio:
-3.7469
EPS:
-0.4804
Net Cash Flow:
$-2.83M
1W Performance:
+56.52%
1M Performance:
+66.67%
6M Performance:
+141.20%
1Y Performance:
-4.76%
1-Day Range:
$1.54
$1.99
1-Week Range:
$1.06
$1.99
52-Week Range:
$0.6765
$2.39
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.80 | 9.52M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuron Limited Adr Stock (IMRN) Latest News
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Immuron LimitedADR (IMRN) Peer Comparison – Compare with Others - Value Research
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results - benzinga.com
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August - benzinga.com
IMRN Stock Jumps As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
IMRN Stock Pops As Immuron Beats Guidance And Advances Pipeline - StocksToTrade
$4.16B US gut health market in sight for Immuron (IMRN) with new PROIBS distribution deal - Stock Titan
Immuron (ASX:IMC; NASDAQ:IMRN) Brings European-Certified Medical Device PROIBS® To U.S. Consumers - Kalkine Media
Immuron Limited WarrantsADR (IMRNW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss - Stock Titan
Immuron Reports FY26 Preliminary Results - Barchart.com
Kazia Therapeutics LimitedADR Peer Comparison – Compare with Others - Value Research
Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development - Stock Titan
Immuron (ASX: IMC) Pushes IMM-529 Forward with FDA Clearance and Partnering Strategy - Kalkine Media
Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference - Stock Titan
Immuron (IMRN) Holds Gains Above $1.10 as Micro-Cap Biotech Finds Buying InterestChannel Breakout - vinanet.vn
PRU Q2 2026 Earnings: EPS Beats Estimates by 14.5% as Prudential Delivers Strong ResultsRevenue Breakdown Analysis - vinanet.vn
GLIBK Q1 2026 Earnings: EPS Misses Estimates by 63.89%, Coming in at $0.45 per ShareTangible Book Value - Vinanet
Immuron Limited (IMRN) Slips 1.8% as ADR Tests Key $1.04 SupportMutual Fund Flow - vinanet.vn
Immuron (NASDAQ: IMRN) outlines FY26 growth, cash runway and CDI IND plans - Stock Titan
Immuron Limited Sponsored ADR Revenue Breakdown – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Revenue Breakdown – LSX:A2DTD8 - TradingView
Immuron Limited (NASDAQ: IMRN) highlights antibody platform at TechKnow Invest - Stock Titan
Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m - Stock Titan
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Sahm
BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits - Kalkine
Immuron (NASDAQ: IMRN) lifts FY26 Travelan sales 6% to AUD$7.7m - Stock Titan
BNY Mellon Boosts Immuron Stake to 44.61% Through ADR Share Deposits by July 2026 - Kalkine Media
AVANTEL.NS Mar 2026 Earnings: EPS of ₹0.27 on Revenue of ₹63.15 CroreOne-Time Loss Impact - vinanet.vn
Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push - Stock Titan
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewswire Inc.
Immuron (ASX:IMC) Pursues Strategic Partnership to Advance FDA IND-Cleared IMM-529 - Kalkine Media
IMRNImmuron Limited ADR Revenue Breakdown - Finviz
A2DTD8 Forecast — Price Target — Prediction for 2027 - TradingView
ANWA Forecast — Price Target — Prediction for 2027 - TradingView
Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue - Stock Titan
Price to earnings forward of Immuron Limited Sponsored ADR – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Actuals & Estimates (NASDAQ:IMRN) - TradingView
Form 6K Immuron Ltd ADR For: 23 June By Investing.com - Investing.com South Africa
Form 6K Immuron Ltd ADR For: 23 June - Investing.com UK
Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back - Stock Titan
Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital - Stock Titan
63MOONS.NS Q2 2026 Earnings: Revenue Surge of 351% YoY but Net Loss PersistsTrough Earnings Signal - Vinanet
ADVAIT.NS Mar 2026 Earnings: Robust Profitability Amidst Expanding OperationsEarnings Beat Streak - vinanet.vn
Immuron (ASX: IMC): Advancing Gastrointestinal Product Portfolio Across Multiple Markets - Kalkine Media
Which stocks have an unusual volume on Thursday? - ChartMill
Immuron (NASDAQ: IMRN) responds to ASX query on share price - Stock Titan
Wondering what's happening in today's after-hours session? - ChartMill
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3 - Stock Titan
Number of shareholders of Immuron Limited Sponsored ADR – LSX:A2DTD8 - TradingView
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):